Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA)

Autor: G.A.P. Nieuwenhuijzen, R.A. Hellingman, Franchette W P J van den Berkmortel, S. Hovenga, H.M. Oosterkamp, T. van Dalen, Sabine C. Linn, E.J. van Dulken, Rudi M. H. Roumen, Maurice J.C. van der Sangen, R.C. van Doorn, M.O. den Boer, R. den Toom, Carolien H. Smorenburg, J.J.M. van der Hoeven, Aafke H. Honkoop, Irene E. G. van Hellemond, H. Potthoff, R. Koelemij, Frans L. G. Erdkamp, A. van Bochove, W.G. van Leeuwen-Breuk, R.J.B. Blaisse, A.M.T. van der Velden, Yvonne Kamm, E.J.C. Vriens, Judith R. Kroep, Erik W. Muller, W.J.B. Mastboom, R. van Hillegersberg, P.C. van der Velden, T. van Voorthuizen, Vivianne C. G. Tjan-Heijnen, J.M. Meerum Terwogt, M.M. Vleugel, A. Vos, J.J. Jansen, Jos J. E. M. Kitzen, G.S. Madretsma, R. Vree, J.K.S. Nuytinck, Luc J. A. Strobbe, J.H. van Dam, P.H.A. Nijhuis, Wilfred K. de Roos, P.P.J.B.M. Schiphorst, B. Jas, E.E.M. Schepers, Q. van Rossum-Schornagel, Petronella G. M. Peer, C.J. van Groeningen, J.G. Haasjes, M.J. Agterof, E.A. Kouwenhoven, Alexander L T Imholz, Caroline M. Seynaeve, M.A. Davidis-van Schoonhoven, M.A.J. de Roos, M.J.P.M. Govaert, J.M.A. Ketel, J.M.G.H. van Riel, M. Jagers, A.J. van Overbeeke, Aart Beeker, J.K. Maring, G.J. Veldhuis, J.W.S. Merkus, Maaike de Boer, Onno R. Guicherit, H.B.A.C. Stockmann, E. Janssens van Vliet, J. de Boer, D.F.S. Kehrer, I.E. Arntz, N.G.J. van Diemen, Koop Bosscha, Hiltje de Graaf, F.A.A. Valster, E.E.M. Weernink, C.T.A.M. van Rossum, M.A. van Dijk, B.C. Tanis, Astrid C P Swinkels, E.J.M. Siemerink, D.W. Sommeijer

Publikováno v: Tjan-Heijnen, V C G, van Hellemond, I E G, Peer, P G M, Swinkels, A C P, Smorenburg, C H, van der Sangen, M J C, Kroep, J R, De Graaf, H, Honkoop, A H, Erdkamp, F L G, van den Berkmortel, F W P J, de Boer, M, de Roos, W K, Linn, S C, Imholz, A L T, Seynaeve, C M & Dutch Breast Cancer Research Group (BOOG) for the DATA Investigators 2017, ' Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA) : a randomised, phase 3 trial ', The Lancet Oncology, vol. 18, no. 11, pp. 1502-1511 . https://doi.org/10.1016/S1470-2045(17)30600-9
The Lancet Oncology, 18(11), 1502-1511
Lancet Oncology, 18, 11, pp. 1502-1511
LANCET ONCOLOGY, 18(11), 1502. Lancet Publishing Group
The Lancet Oncology, 18(11), 1502-1511. Lancet Publishing Group
Lancet oncology, 18(11), 1502-1511. Elsevier Science
Lancet Oncology, 18(11), 1502-1511. Lancet Publishing Group
Lancet Oncology, 18, 1502-1511

Item does not contain fulltext BACKGROUND: The effect of extended adjuvant aromatase inhibition in hormone receptor-positive breast cancer after sequential endocrine therapy of tamoxifen followed by an aromatase inhibitor for a 5-year treatment perio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::772ac93cab50bc31223c7dc7ba3cb291
https://doi.org/10.1016/s1470-2045(17)30600-9

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis

Autor: Rob L. H. Jansen, Ron H.N. van Schaik, Henk-Jan Guchelaar, Johanna E.A. Portielje, Paul Hamberg, Didier Meulendijks, Jos H. Beijnen, Emma Kienhuis, Ron H.J. Mathijssen, Hans Gelderblom, Femke M. de Man, Frank J.F. Jeurissen, Geert W.J. Frederix, Arnold Baars, Jan H.M. Schellens, Helga J. Droogendijk, Marlène H.W. van de Poel, Hilde Rosing, Linda M. Henricks, Albert J. ten Tije, Annemieke Cats, Carin A.T.C. Lunenburg, Caroline M.P.W. Mandigers, Erik van Werkhoven, André B.P. van Kuilenburg, Peter Nieboer, Geert Jan Creemers, Miriam Koopman, Vincent O. Dezentjé, Alexander L T Imholz, Jesse J. Swen

Publikováno v: The Lancet Oncology, 19(11), 1459-1467
The Lancet Oncology, 19(11), 1459. Lancet Publishing Group
LANCET ONCOLOGY, 19(11), 1459. Lancet Publishing Group
The Lancet Oncology
Lancet oncology, 19(11), 1459-1467. Elsevier Science
lancet oncology, 19(11), 1459-1467. Lancet Publishing Group
Lancet Oncology, 19(11), 1459-1467. Lancet Publishing Group

Background Fluoropyrimidine treatment can result in severe toxicity in up to 30% of patients and is often the result of reduced activity of the key metabolic enzyme dihydropyrimidine dehydrogenase (DPD), mostly caused by genetic variants in the gene

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4283cc80c2ca08cc0f0a136e40a12b84
http://hdl.handle.net/1887/95617

Ovarian Function Recovery During Anastrozole in Breast Cancer Patients With Chemotherapy-Induced Ovarian Function Failure

Autor: Astrid C P Swinkels, Maaike de Boer, Wilfred K. de Roos, Carolien H. Smorenburg, Aafke H. Honkoop, Judith R. Kroep, Alexander L T Imholz, Jos J. E. M. Kitzen, Franchette W P J van den Berkmortel, Vivianne C. G. Tjan-Heijnen, Hiltje de Graaf, Petronella G. M. Peer, Caroline M. Seynaeve, Irene E. G. van Hellemond, Sabine C. Linn, Ingeborg J. H. Vriens, Maurice J.C. van der Sangen, Frans L. G. Erdkamp

Publikováno v: Journal of the National Cancer Institute, 109, 12, pp. djx074-djx074
Journal of the National Cancer Institute, 109(12):074. Oxford University Press
Journal of the National Cancer Institute, 109, djx074-djx074
Journal of the National Cancer Institute, 109(12):djx074. Oxford University Press

Background: Aromatase inhibitors (AIs) are given as adjuvant therapy for hormone receptor-positive breast cancer in postmenopausal women, also to those with chemotherapy-induced ovarian function failure. The current analysis reports on endocrine data

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69cc143e5baabc329cbcf39777e1e254
https://doi.org/10.1093/jnci/djx074